Keywords
pediatrics
methotrexate
neutropenia
anemia
How to Cite
Abstract
Introduction: Acute lymphocytic leukemia (ALL) is the most common childhood malignancy. Treatment includes 3 phases. During the cosolidation phase the use of methrotexate in different doses, depending on the risk classification, is the treatments main pilar.
Objective: To Estimate the presence of febrile neutropenia, anemia and thrombocytopenia in patients with ALL receiving methotrexate during the consolidation phase at a dose of 5 g/m2 compared to patients who received doses of 2 g/m2.
Methods: Review clinical records of all patients between 1 and 15 years old treated for ALL at the Oncology Center of Javeriana University between January 1/2012 and March 10/2014.
Results: Information of 66 cycles of chemotherapy were collected, of which 31 corresponded to 2 g/m2 and 35 to 5 g/m2 applications. The frequency of febrile neutropenia in the group 2 g/m2 was 25 % and 34 % in the group 5g/m2, which resembles literature reports.
Conclusion: The use of high-dose of methotrexate for the management of ALL in our area did not represent an increase in haematological toxicity compared to low dose group. And there is enough evidence of improved cure rates of the disease.
Margolin J, Steuber P, Poplack D. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DC, editors. Principles and practices of pediatric oncology. 5th ed. Philadelphia: Lippinccott Williams and Wilkins; 2006. p. 538-90.
Piñeros M, Pardo C, Otero J, Viscaíno M, Álvarez V. Protocolo de vigilancia centinela en salud pública en leucemias agudas pediátricas. Bogotá: Instituto Nacional de Salud, Instituto Nacional de Cancerología, Ministerio de Protección Social de Colombia; 2008.
Pui C-H. Acute lymphoblastic leukemia. In: Pui C-H, editor. Childhood leukaemia. 2nd ed. Memphis: St. Jude Children´s Research Hospital; 2006. p. 439-72.
Ministerio de Salud y Protección Social, Colciencias. Guías de atención integral [internet]. Disponible en: http://www.guiascolcienciasminproteccionsocialalianzacinets.org/index.php?option=com_wrapper&view=wrapper&Itemid=181.
Paganini H, Santolaya MH. Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer: consenso de la Sociedad Latinoamericana de Infectología Pediátrica. Rev Chil Infect. 2011;28(Supl 1):10-38.
Kappor G, Sinha R, Abedin S. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer. 2012;59(3):448-53.
Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165-74.
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.